Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

18 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Neoadjuvant Systemic Therapy in Early Breast Cancer: Results of a Prospective Observational Multicenter BRIDE Study.
Gori S, Fabi A, Angiolini C, Turazza M, Salvini P, Ferretti G, Cretella E, Gianni L, Bighin C, Toss A, Zamagni C, Vici P, De Rossi C, Russo A, Bisagni G, Frassoldati A, Borgato L, Cariello A, Cappelletti C, Bordonaro R, Cinieri S, Modena A, Valerio M, Alvisi MF, De Simone I, Galli F, Rulli E, Santoni A, Nicolis F. Gori S, et al. Among authors: alvisi mf. Cancers (Basel). 2023 Oct 4;15(19):4852. doi: 10.3390/cancers15194852. Cancers (Basel). 2023. PMID: 37835546 Free PMC article.
Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Fantini MC, Vecchi M, Geginat J, Caprioli F. Coletta M, et al. Among authors: alvisi mf. J Crohns Colitis. 2020 Sep 16;14(9):1190-1201. doi: 10.1093/ecco-jcc/jjaa035. J Crohns Colitis. 2020. PMID: 32100016 Clinical Trial.
High-dose ivermectin for early treatment of COVID-19 (COVER study): a randomised, double-blind, multicentre, phase II, dose-finding, proof-of-concept clinical trial.
Buonfrate D, Chesini F, Martini D, Roncaglioni MC, Ojeda Fernandez ML, Alvisi MF, De Simone I, Rulli E, Nobili A, Casalini G, Antinori S, Gobbi M, Campoli C, Deiana M, Pomari E, Lunardi G, Tessari R, Bisoffi Z. Buonfrate D, et al. Among authors: alvisi mf. Int J Antimicrob Agents. 2022 Feb;59(2):106516. doi: 10.1016/j.ijantimicag.2021.106516. Epub 2022 Jan 6. Int J Antimicrob Agents. 2022. PMID: 34999239 Free PMC article. Clinical Trial.
Predicting the Role of DNA Polymerase β Alone or with KRAS Mutations in Advanced NSCLC Patients Receiving Platinum-Based Chemotherapy.
Alvisi MF, Ganzinelli M, Linardou H, Caiola E, Lo Russo G, Cecere FL, Bettini AC, Psyrri A, Milella M, Rulli E, Fabbri A, De Maglie M, Romanelli P, Murray S, Ndembe G, Broggini M, Garassino MC, Marabese M. Alvisi MF, et al. J Clin Med. 2020 Jul 30;9(8):2438. doi: 10.3390/jcm9082438. J Clin Med. 2020. PMID: 32751518 Free PMC article.
Single-arm, open label prospective trial to assess prediction of the role of ERCC1/XPF complex in the response of advanced NSCLC patients to platinum-based chemotherapy.
Ganzinelli M, Linardou H, Alvisi MF, Caiola E, Lo Russo G, Cecere FL, Bettini AC, Psyrri A, Milella M, Rulli E, Fabbri A, De Maglie M, Romanelli P, Murray S, Broggini M, Marabese M, Garassino MC. Ganzinelli M, et al. Among authors: alvisi mf. ESMO Open. 2021 Feb;6(1):100034. doi: 10.1016/j.esmoop.2020.100034. Epub 2021 Jan 7. ESMO Open. 2021. PMID: 33422766 Free PMC article.
Corrigendum to: Immunological Variables Associated With Clinical and Endoscopic Response to Vedolizumab in Patients With Inflammatory Bowel Diseases.
Coletta M, Paroni M, Alvisi MF, De Luca M, Rulli E, Mazza S, Facciotti F, Lattanzi G, Strati F, Abrignani S, Claudio Fantini M, Vecchi M, Geginat J, Caprioli F. Coletta M, et al. Among authors: alvisi mf. J Crohns Colitis. 2022 Jul 14;16(6):1010. doi: 10.1093/ecco-jcc/jjab107. J Crohns Colitis. 2022. PMID: 34850867 No abstract available.
Randomized phase II trial of weekly paclitaxel vs. cediranib-olaparib (continuous or intermittent schedule) in platinum-resistant high-grade epithelial ovarian cancer.
Colombo N, Tomao F, Benedetti Panici P, Nicoletto MO, Tognon G, Bologna A, Lissoni AA, DeCensi A, Lapresa M, Mancari R, Palaia I, Tasca G, Tettamanzi F, Alvisi MF, Rulli E, Poli D, Carlucci L, Torri V, Fossati R, Biagioli E; BAROCCO study group. Colombo N, et al. Among authors: alvisi mf. Gynecol Oncol. 2022 Mar;164(3):505-513. doi: 10.1016/j.ygyno.2022.01.015. Epub 2022 Jan 19. Gynecol Oncol. 2022. PMID: 35063281 Clinical Trial.
18 results